High prevalence of gene abnormalities in young patients with lung cancer
High prevalence of gene abnormalities in young patients with lung cancer
复制标题
DOI：
10.3978/j.issn.2072-1439.2012.12.02
复制
发表时间：
2013-02-01
影响因子：
2.5
通讯作者：
Takahashi, Kazuhisa
中科院分区：
文献类型：
--
作者：
Nagashima, Osamu;Ohashi, Rina;Takahashi, Kazuhisa
背景资料：最近，肺腺癌中的驱动癌基因被鉴定，并且在临床环境中引入了几种分子靶向剂。材料和方法：对2004年7月至2010年3月在顺天堂大学浦安医院或顺天堂大学医院就诊的12例40岁以下的肺腺癌患者的埃格激活突变、EML 4-ALK融合基因和K-ras突变等驱动癌基因状态进行分析。4例患者存在埃格基因突变。7例EGFR突变阴性患者中有5例显示EML 4-ALK基因融合阳性结果。结论：12例乳腺癌中9例（75%）存在埃格突变和EML 4-ALK融合基因的驱动癌基因。对年轻非小细胞肺癌患者进行基因异常检查是提供最佳治疗的必要条件。
Background: Recently, driver oncogenes in adenocarcinoma of the lung were identified, and several molecular target agents were introduced in the clinical setting. However, there are few reports on the frequency of gene abnormalities in young patients with lung cancer.Materials and methods: Twelve patients with lung adeno carcinoma aged 40 or younger at Juntendo University Urayasu Hospital or Juntendo University Hospital from July 2004 to March 2010 were analyzed for driver oncogene status including EGER activating mutation, EML4-ALK fusion gene, and K-ras mutation.Results: Four patients showed EGER gene mutation. Five out of 7 EGFR mutation-negative patients showed positive results for EML4-ALK gene fusion. One case whose EGFR mutation was indeterminate.Conclusions: Driver oncogene including EGER mutation and EML4-ALK fusion gene was identified in 9 of 12 cases (75%). Examination of gene abnormalities is essential in young patients with non-small cell lung cancer to provide the best treatment.